Evidence map›Paper›PMID 39147711›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2024

[Non-small Cell Lung Cancer with Metachronous Mutations of EGFR and ALK Genes: 
A Case Report and Literature Review].

Xiaoyan Kong, Mingjuan Wang, Qiaoyun Tang, Mengyu Sun, Jianjun Hu

Abstract readCase ReportsReviewEnglish Abstract
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaoyan KongDepartment of Oncology, Nanjing Tongren Hospital, Nanjing 211102, China.
Mingjuan WangDepartment of Oncology, Nanjing Tongren Hospital, Nanjing 211102, China.
Qiaoyun TangDepartment of Oncology, Nanjing Tongren Hospital, Nanjing 211102, China.
Mengyu SunDepartment of Oncology, Nanjing Tongren Hospital, Nanjing 211102, China.
Jianjun HuDepartment of Oncology, Nanjing Tongren Hospital, Nanjing 211102, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple primary lung cancer (MPLC) refers to patients with two or more primary lesions of lung cancer. It can be divided into synchronous MPLC (sMPLC) and metachronous MPLC (mMPLC) based on the timing of occurrence. In recent years, the detection rate of MPLC has gradually increased. However, considerable controversy exists in distinguishing MPLC from intrapulmonary metastasis (IM), especially when the histopathological types are identical. Given the significant differences in treatment strategies and prognosis in clinical practice currently, accurate diagnosis of MPLC is crucial for personalized precision therapy. Molecular genetics and sequencing technologies offer effective strategies for assessing the clonal origin of tumors. There have been reports of coexisting mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) fusion genes in non-small cell lung cancer, but case of EGFR mutation following an ALK mutation has not been mentioned. This article accurately diagnoses and retrospectively analyzes the clinical data of a case of ALK mutant adenocarcinoma in a male patient who developed an EGFR mutation with multiple metastases four years after surgery, and reviews the relevant literature. This paper aims to deepen the understanding of mMPLC and provide clinical references for the diagnosis and treatment of such patients.
.

Indexed as

Anaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsMutationAgedHumansMaleReceptor Protein-Tyrosine KinasesALK protein, humanAnaplastic Lymphoma KinaseEGFR protein, humanErbB ReceptorsReceptor Protein-Tyrosine KinasesALKEGFRIntrapulmonary metastasisMetachronous multiple primary lung cancer

Identifiers

PMID39147711
PMCPMC11331256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.